Aravax secures FDA Fast Track designation for PVX108 peanut allergy immunotherapy

Aravax secured FDA Fast Track designation for PVX108, a novel peanut allergy immunotherapy, enabling accelerated development and rolling review in the US. The Phase II trial is underway with data expected later in 2026, positioning PVX108 ahead of competing programs in clinical progress.

This Wire brief sits within Fusion42's coverage of Biotech.